adra2b Antibody

What is ADRA2B and why are antibodies against it important for research?

ADRA2B (adrenergic, alpha-2B-, receptor) is a member of the G protein-coupled receptor superfamily that mediates catecholamine-induced inhibition of adenylate cyclase through G proteins . ADRA2B plays crucial roles in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system .

Antibodies against ADRA2B are essential research tools for:

• Studying receptor expression in various tissues and cell types

• Investigating receptor localization at cellular and subcellular levels

• Examining receptor phosphorylation and desensitization mechanisms

• Analyzing the functional consequences of ADRA2B polymorphisms

The receptor's involvement in cardiovascular functions through control of blood vessel tone and cardiac output makes it a significant target for understanding physiological and pathological processes .

What applications are ADRA2B antibodies typically used for?

ADRA2B antibodies have been validated for multiple research applications including:

Different antibodies have specific optimal dilutions, and pilot experiments should be conducted to determine the optimal conditions for each specific application and sample type .

What species reactivity should I consider when selecting an ADRA2B antibody?

When selecting an ADRA2B antibody, species reactivity is a critical consideration:

It's essential to confirm the antibody's reactivity with your target species. While some antibodies show cross-reactivity across species due to conserved epitopes, others are highly species-specific . Always verify the antibody's reactivity through literature or validation data before designing experiments with new species samples.

How can ADRA2B antibodies be used to study the Glu301-303 deletion polymorphism and its functional consequences?

The Glu301-303 deletion polymorphism in ADRA2B has significant functional implications that can be investigated using specific antibodies:

Methodological approach:

• Phosphorylation studies: Use anti-phosphoserine antibodies in combination with ADRA2B antibodies to compare phosphorylation levels between wild-type and Del ADRA2B variants following agonist stimulation .

• Desensitization analysis: Employ [35S]GTPγS binding assays to measure G-protein coupling efficiency after agonist pretreatment, comparing wild-type and Del ADRA2B receptors .

• Functional assessment: Utilize ADRA2B antibodies in chromaffin cell models (like PC12) to investigate the impact of the polymorphism on catecholamine secretion through immunoprecipitation and western blotting .

Research has shown this polymorphism exhibits "impaired agonist-promoted phosphorylation and desensitization in PC12 cells, resulting in enhanced inhibitory function against cholinergic-induced catecholamine secretion in vitro" . This finding has implications for conditions characterized by sympathetic/catecholaminergic overstimulation, such as heart failure, hypertension, and hyperthyroidism .

What methodological approaches can be used to differentiate between the three alpha-2 adrenergic receptor subtypes (alpha-2A, alpha-2B, and alpha-2C)?

Differentiating between the three highly homologous alpha-2 adrenergic receptor subtypes requires careful antibody selection and experimental design:

Antibody-based approaches:

• Epitope selection: Use antibodies targeting unique regions, such as the second extracellular loop or C-terminal regions that differ between subtypes .

• Subtype-specific antibodies: For example, Anti-α2B-Adrenergic Receptor (extracellular) Antibody targets an epitope corresponding to amino acid residues 160-174 of rat α2B-adrenoceptor with replacement of cysteine 169 with serine .

• Validation with blocking peptides: Confirm specificity by using blocking peptides specific to each subtype. Signal abolishment upon peptide coincubation confirms antibody specificity .

Complementary approaches:

• Pharmacological profiling: Use subtype-specific agonists and antagonists to corroborate antibody-based findings.

• Genetic approaches: Employ siRNA knockdown or knockout models to validate antibody specificity.

• Recombinant expression systems: Test antibodies against cells expressing single receptor subtypes to confirm specificity.

When reporting findings, always indicate the specific subtype and validation methods used to ensure result reproducibility and reliability.

How can ADRA2B antibodies contribute to understanding the role of this receptor in metabolic disorders and obesity?

ADRA2B antibodies can be instrumental in elucidating the receptor's role in metabolic disorders through several research approaches:

Tissue expression and localization studies:

• Use immunohistochemistry and immunofluorescence with ADRA2B antibodies to map receptor distribution in metabolically relevant tissues (adipose tissue, pancreas, liver, hypothalamus) .

• Compare receptor expression patterns between lean and obese subjects, focusing on potential alterations in receptor density or localization.

Polymorphism investigation:
The Glu301-303 deletion polymorphism has been associated with "reduced basal metabolic rate in obese subjects and may therefore contribute to the pathogenesis of obesity" . Research approaches include:

• Genotyping populations to identify carriers of the polymorphism.

• Using ADRA2B antibodies to compare receptor expression, signaling, and trafficking between wild-type and polymorphic variants.

• Correlating receptor function with metabolic parameters.

Mechanistic studies:

• Investigate ADRA2B-mediated regulation of insulin secretion, as the receptor has been implicated in "first-phase insulin secretion that may predict impaired glucose tolerance" .

• Examine the association between ADRA2B and eIF-2B (a guanine nucleotide exchange protein involved in translation regulation), which may impact metabolic processes .

• Study the receptor's role in catecholamine-mediated lipolysis and thermogenesis in adipose tissue.

These approaches collectively provide a comprehensive understanding of how ADRA2B contributes to metabolic regulation and obesity pathogenesis.

What are the optimal conditions for immunohistochemistry (IHC) applications using ADRA2B antibodies?

Successful IHC with ADRA2B antibodies requires careful optimization of several parameters:

Sample preparation:

• Fixation: Paraformaldehyde fixation is commonly used for ADRA2B detection, with both paraffin-embedded and frozen sections yielding good results .

• Antigen retrieval: For paraffin sections, TE buffer pH 9.0 is suggested. Alternatively, citrate buffer pH 6.0 may be used, but comparative testing is recommended .

Staining protocol:

• Antibody dilution: Start with 1:50-1:500 dilution range for most ADRA2B antibodies, optimizing based on signal-to-noise ratio .

• Incubation conditions: Typically overnight at 4°C or 1-2 hours at room temperature.

• Detection systems: Both chromogenic (e.g., DAB with hematoxylin counterstain) and fluorescent detection systems work well with ADRA2B antibodies .

Validation controls:

• Positive controls: Human gliomas tissue has shown positive IHC detection with some ADRA2B antibodies .

• Negative controls: Include omission of primary antibody and, when available, pre-absorption with specific blocking peptides .

• Tissue-specific expression: Respiratory epithelium of bronchioli in rat lung and cerebellar nuclei in mouse brain have shown positive ADRA2B expression .

For co-localization studies, DAPI counterstaining for cell nuclei can provide structural context for receptor localization in tissues .

What considerations are important when designing Western blot experiments to detect ADRA2B?

Detecting ADRA2B via Western blot requires attention to several technical aspects:

Sample preparation:

• Tissue selection: Various tissues express ADRA2B, including brain, kidney, lung, liver, and certain cell lines (MCF7, HepG2, 293T) .

• Protein extraction: Standard lysis buffers containing protease inhibitors are suitable. For membrane proteins like ADRA2B, consider detergent-based extraction methods.

• Protein amount: Load 10-30 μg of total protein per lane for most tissue lysates .

Technical parameters:

• Antibody dilution: Varies widely based on the specific antibody:

  • Some antibodies work at high dilutions (1:10,000)

  • Others require stronger concentrations (1:200-1:2000)

• Expected molecular weight: ADRA2B has a calculated molecular weight of approximately 50 kDa .

• Secondary antibody selection: Match to the host species of the primary antibody (e.g., goat anti-rabbit HRP for rabbit primary antibodies) .

Validation strategies:

• Blocking peptides: When available, pre-incubate the antibody with a specific blocking peptide to confirm band specificity .

• Positive controls: Use known ADRA2B-expressing tissues or cell lines (e.g., human fetal brain, MCF7, HepG2, 293T cells) .

• Molecular weight verification: Confirm that the detected band corresponds to the expected size of 50 kDa. Be aware that post-translational modifications may alter the apparent molecular weight.

How should flow cytometry experiments be designed and optimized for ADRA2B detection?

Flow cytometry for ADRA2B detection requires specific considerations due to its nature as a membrane receptor with intracellular components:

Sample preparation:

• Cell types: HEK-293 cells and WEHI B-cell lymphoma have been successfully used for ADRA2B detection by flow cytometry .

• Fixation and permeabilization: For intracellular detection, appropriate permeabilization is crucial while preserving epitope integrity.

Antibody parameters:

• Concentration: Typically use 0.25 μg per 10^6 cells in a 100 μl suspension for intracellular detection .

• Controls:

  • Unstained cells

  • Secondary antibody only

  • Isotype control

  • Blocking peptide competition (when available)

Protocol optimization:

• Surface vs. intracellular detection: Both approaches can be used depending on the antibody's epitope location:

  • Surface detection works for antibodies targeting extracellular domains

  • Intracellular detection requires permeabilization but can offer stronger signals

• Data analysis: Present flow cytometry data with proper controls, showing shifts in fluorescence intensity with antibody addition. For example:

  • Cells alone (negative control)

  • Cells + secondary antibody (background control)

  • Cells + ADRA2B antibody + secondary antibody (experimental condition)

Following standardized protocols and including appropriate controls ensures reliable and reproducible ADRA2B detection by flow cytometry.

How can I address non-specific binding issues when using ADRA2B antibodies?

Non-specific binding can compromise experimental results when working with ADRA2B antibodies. Here are systematic approaches to identify and minimize this issue:

Identifying non-specific binding:

• Multiple bands in Western blot: When observing bands other than the expected 50 kDa, consider the following validation steps:

  • Compare with a blocking peptide control

  • Test in tissues/cells known to be negative for ADRA2B

  • Use multiple antibodies targeting different epitopes

• Diffuse staining in IHC/IF: Non-specific staining typically appears as:

  • Background staining that doesn't follow expected cellular distribution

  • Staining that persists in negative control tissues

  • Signal that doesn't diminish with blocking peptide competition

Optimization strategies:

• Blocking optimization:

  • Extend blocking time (1-2 hours)

  • Try different blocking agents (BSA, normal serum, commercial blockers)

  • Use dual blocking with both protein-based and detergent-based blockers

• Antibody conditions:

  • Titrate antibody concentration (try more dilute solutions)

  • Reduce incubation time or temperature

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

• Washing procedures:

  • Increase wash duration and number of washes

  • Use higher salt concentration in wash buffers

  • Add low concentrations of detergent to wash buffers

• Validation approaches:

  • Use blocking peptides specific to the ADRA2B epitope

  • Include genetic controls (knockdown/knockout samples) when available

  • Compare results across multiple ADRA2B antibodies targeting different epitopes

These strategies should be applied systematically, changing one variable at a time to identify the optimal conditions for specific ADRA2B detection.

How should I interpret contradictory findings when using different ADRA2B antibodies?

Contradictory results between different ADRA2B antibodies are not uncommon and require careful analysis:

Sources of discrepancy:

• Epitope differences: Antibodies targeting different regions of ADRA2B may yield different results:

  • Extracellular domain antibodies (e.g., amino acids 160-174)

  • Central region antibodies (e.g., amino acids 343-369)

  • N-terminal (AA 1-100) vs. C-terminal targeting antibodies

• Post-translational modifications: Different antibodies may have varying sensitivities to:

  • Phosphorylated forms (especially relevant when studying receptor desensitization)

  • Glycosylated forms

  • Conformational states (active vs. inactive receptor)

• Methodological variations: Consider differences in:

  • Sample preparation (fixation methods, extraction protocols)

  • Detection systems (chromogenic vs. fluorescent)

  • Antibody concentrations and incubation conditions

Resolution strategies:

• Antibody validation hierarchy:

  • Prioritize antibodies validated with blocking peptides, knockout controls, or recombinant expression systems

  • Consider antibodies that have been validated across multiple applications

  • Check publication records for independent validation

• Complementary approaches:

  • Combine antibody-based methods with functional assays

  • Use mRNA detection methods (qPCR, in situ hybridization) to correlate with protein findings

  • Apply genetic tools (siRNA, CRISPR) to confirm specificity

• Transparent reporting:

  • Document all antibody details (catalog number, lot, dilution, epitope)

  • Report both positive and negative findings

  • Acknowledge limitations and potential alternative interpretations

What are the key considerations when studying the functional implications of ADRA2B polymorphisms using antibody-based approaches?

Studying ADRA2B polymorphisms, particularly the Glu301-303 deletion variant, requires specialized approaches:

Experimental design considerations:

• Genotyping: First identify the polymorphic status of your experimental samples using molecular techniques:

  • PCR-based genotyping

  • Sequencing verification

  • Use of characterized cell lines or samples

• Antibody selection:

  • Ensure the antibody epitope is not affected by the polymorphism location

  • For the Glu301-303 deletion, avoid antibodies targeting the 301-303 region

  • Consider using multiple antibodies targeting different domains

• Functional readouts:

  • Phosphorylation studies using anti-phosphoserine antibodies to examine desensitization

  • G-protein coupling assays ([35S]GTPγS binding)

  • Catecholamine secretion measurements in appropriate cell models

Interpretation challenges:

• Expression vs. function: Distinguish between:

  • Changes in receptor expression levels

  • Alterations in functional properties (e.g., phosphorylation, desensitization)

  • Differences in subcellular localization

• Context dependency:

  • Cell type-specific effects (e.g., different in PC12 vs. other cell types)

  • Influence of other genetic factors (genetic background)

  • Physiological state (stress, disease conditions)

• Translational relevance:

  • Connect cellular findings to physiological outcomes

  • Consider the polymorphism's associations with clinical phenotypes:

    • Reduced basal metabolic rate in obesity

    • Acute coronary events and sudden cardiac death risk

    • Impaired endothelial function

    • First-phase insulin secretion effects

When reporting findings, clearly describe both the genotypic characteristics and the specific functional parameters measured, as the polymorphism may affect some but not all aspects of receptor function.

How can single-cell approaches be integrated with ADRA2B antibody detection for advanced research applications?

Integrating single-cell approaches with ADRA2B antibody detection offers powerful insights into receptor heterogeneity and function:

Single-cell immunodetection approaches:

• Flow cytometry and cell sorting:

  • Use validated ADRA2B antibodies (e.g., Alexa Fluor 405-conjugated)

  • Optimize for intracellular or surface detection based on epitope location

  • Sort ADRA2B-positive cells for downstream analysis

• Mass cytometry (CyTOF):

  • Use metal-conjugated ADRA2B antibodies

  • Combine with other markers to create comprehensive cellular phenotypes

  • Particularly valuable for matched antibody pairs in PBS-only formulation that are ready for conjugation

• Single-cell imaging:

  • Super-resolution microscopy to examine receptor clustering and distribution

  • Live-cell imaging with minimally disruptive antibody fragments or nanobodies

  • Multiplexed imaging with other cellular markers

Integration with other single-cell technologies:

• Single-cell RNA-seq plus protein (CITE-seq):

  • Correlate ADRA2B protein levels with transcriptome-wide gene expression

  • Examine relationships between receptor expression and cellular states

• Spatial transcriptomics with immunodetection:

  • Map ADRA2B protein distribution in tissue context

  • Correlate with spatial gene expression patterns

• Functional readouts at single-cell level:

  • Calcium imaging in ADRA2B-labeled cells

  • Electrophysiology with immunoidentified cells

  • Single-cell secretion assays (e.g., for catecholamines)

Analytical considerations:

• Heterogeneity assessment:

  • Quantify cell-to-cell variation in ADRA2B expression

  • Identify distinct cellular subpopulations based on receptor levels

  • Correlate with functional parameters

• Rare cell identification:

  • Detect and characterize rare ADRA2B-expressing cells in mixed populations

  • Track receptor dynamics in response to stimuli at single-cell resolution

• Quantitative analysis:

  • Apply computational approaches to extract receptor distribution patterns

  • Use machine learning for complex phenotype identification

  • Implement trajectory analysis for dynamic receptor responses

These integrated approaches provide unprecedented resolution of ADRA2B biology in heterogeneous cell populations and complex tissues.

What are the critical factors to consider when developing multiplex assays that include ADRA2B antibodies?

Developing multiplex assays that incorporate ADRA2B antibodies requires careful consideration of several technical factors:

Antibody compatibility:

• Host species diversity: When combining multiple antibodies, select those raised in different host species to enable simultaneous detection with species-specific secondary antibodies.

• Matched antibody pairs: Several ADRA2B antibodies are specifically designed as matched pairs for multiplex applications:

  • MP51152-3: 60802-4-PBS (capture) and 60802-5-PBS (detection)

  • MP51152-2: 60802-3-PBS (capture) and 60802-2-PBS (detection)

  • MP51152-4: 60802-1-PBS (capture) and 60802-3-PBS (detection)

• Buffer compatibility: Use antibodies stored in compatible buffers; PBS-only formulations are ideal for multiplex applications requiring conjugation .

Application-specific considerations:

• Cytometric bead arrays:

  • Ensure antibodies have been validated specifically for this application

  • Optimize bead coating density and antibody concentrations

  • Validate specificity in the multiplex context

• Multiplex imaging:

  • Select fluorophores with minimal spectral overlap

  • Consider photobleaching characteristics

  • Optimize antibody order for sequential staining approaches

• Multiplex ELISA/protein arrays:

  • Test for cross-reactivity between assay components

  • Include appropriate controls for each antibody component

  • Optimize washing steps to minimize background

Validation requirements:

• Single vs. multiplex comparison: Test each antibody individually before combining them to establish baseline performance.

• Cross-reactivity assessment: Systematically test for potential cross-reactions between antibodies, especially when targeting related receptor subtypes.

• Dynamic range verification: Ensure that multiplex detection doesn't compromise the sensitivity or dynamic range for ADRA2B detection.

By addressing these factors methodically, researchers can develop robust multiplex assays that include ADRA2B antibodies while maintaining specificity and sensitivity.

How can I ensure reliable detection of ADRA2B in complex tissue samples like brain or adrenal gland?

Detecting ADRA2B in complex tissues presents unique challenges that require specialized approaches:

Sample preparation optimization:

• Fixation protocols:

  • For brain tissue: Perfusion fixation has been successfully used for ADRA2B detection in mouse brain

  • For adrenal tissue: Consider shorter fixation times to preserve epitope integrity

• Section preparation:

  • Both paraffin-embedded and frozen sections can be used

  • Paraffin sections: Use TE buffer pH 9.0 for antigen retrieval

  • Frozen sections: Optimize section thickness (typically 10-20 μm for brain)

• Region-specific considerations:

  • Brain: ADRA2B has been detected in cerebellar nuclei of mouse brain

  • Adrenal: Consider the distinct zones of the adrenal gland when analyzing distribution

Detection strategies:

• Signal amplification:

  • Consider tyramide signal amplification for low-abundance detection

  • Use high-sensitivity detection systems (e.g., polymer-based detection)

  • Extend primary antibody incubation times (overnight at 4°C)

• Background reduction:

  • Extended blocking with serum matching the host of the secondary antibody

  • Include 0.1-0.3% Triton X-100 in antibody diluent

  • Consider autofluorescence quenching for fluorescent applications in brain tissue

• Co-localization approaches:

  • Combine ADRA2B detection with cell-type specific markers

  • For brain: Use neuronal, glial, or vascular markers for context

  • For adrenal: Consider chromaffin cell markers or zone-specific markers

Validation in complex tissues:

• Anatomical correlation:

  • Compare ADRA2B distribution with known expression patterns

  • In brain, ADRA2B has been detected in cerebellar molecular and granule layers

• Multiple antibody validation:

  • Use antibodies targeting different ADRA2B epitopes

  • Compare polyclonal and monoclonal antibody staining patterns

• Complementary approaches:

  • Correlate protein detection with mRNA localization (in situ hybridization)

  • Consider receptor autoradiography with selective ligands

  • Use genetic models (knockout controls when available)

These approaches help ensure reliable ADRA2B detection in complex tissues where cellular heterogeneity and matrix effects can complicate antibody-based detection.

What strategies can researchers employ to study post-translational modifications of ADRA2B using antibody-based approaches?

Studying post-translational modifications (PTMs) of ADRA2B requires specialized antibody-based strategies:

Phosphorylation analysis:

• Phospho-specific antibodies:

  • Use anti-phosphoserine antibodies for general phosphorylation assessment

  • Consider site-specific phospho-antibodies when available

• Experimental design:

  • Stimulate cells with agonists (e.g., UK14304, a selective α2-AR agonist)

  • Use GRK inhibitors to block receptor phosphorylation

  • Compare wild-type vs. polymorphic variants (e.g., Glu301-303 deletion)

• Detection methods:

  • Immunoprecipitate ADRA2B first, then probe with phospho-specific antibodies

  • Use phosphatase inhibitors throughout sample preparation

  • Consider Phos-tag gels for enhanced separation of phosphorylated species

Glycosylation assessment:

• Enzymatic treatments:

  • Compare apparent molecular weight before and after PNGase F treatment

  • Use O-glycosidase for O-linked glycan removal

  • Employ site-specific mutagenesis of predicted glycosylation sites

• Lectin-based approaches:

  • Combine ADRA2B antibodies with specific lectins for glycan detection

  • Use lectin affinity chromatography followed by ADRA2B immunoblotting

Ubiquitination and SUMOylation:

• Co-immunoprecipitation approaches:

  • Immunoprecipitate ADRA2B, then probe for ubiquitin or SUMO

  • Use proteasome inhibitors to accumulate ubiquitinated species

• Lysine-mutant approaches:

  • Create lysine-to-arginine mutations at potential modification sites

  • Compare wild-type and mutant receptor modification patterns

General considerations:

• Sample preparation:

  • Use rapid lysis methods to preserve labile modifications

  • Include appropriate inhibitors (phosphatase, deubiquitinase, protease)

  • Consider subcellular fractionation to enrich for relevant compartments

• Controls and validation:

  • Include positive controls with known modifications

  • Use pharmacological manipulations to alter modification state

  • Employ mass spectrometry to confirm antibody-based findings

• Functional correlation:

  • Link PTM detection to functional outcomes (e.g., desensitization, internalization)

  • Compare modification patterns between normal and pathological states

  • Examine temporal dynamics of modifications following receptor activation

These approaches provide comprehensive insights into the complex regulation of ADRA2B through post-translational modifications.